Jump to content

Mephenesin

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Mephenesin
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 3-(2-methylphenoxy)propane-1,2-diol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.000.389 Edit this at Wikidata
Chemical and physical data
FormulaC10H14O3
Molar mass182.219 g·mol−1
3D model (JSmol)
  • O(c1ccccc1C)CC(O)CO
  • InChI=1S/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3 checkY
  • Key:JWDYCNIAQWPBHD-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Mephenesin (INN), also called myanesin,[1][2] is a centrally acting muscle relaxant. It can be used as an antidote for strychnine poisoning. Mephenesin however presents with the major drawbacks of having a short duration of action and a much greater effect on the spinal cord than the brain, resulting in pronounced respiratory depression at clinical doses and therefore a very low therapeutic index. It is especially dangerous and potentially fatal in combination with alcohol and other depressants.[3] Mephenesin was the inspiration for the synthesis of a derivative of 1,3-propanediol, meprobamate, by Bernard Ludwig and Frank Berger,[4] the first tranquilizer to see widespread clinical use. Mephenesin is no longer available in North America but is used in Italy and a few other countries.[5] Its use has largely been replaced by the related drug methocarbamol, which is better absorbed.[6]

Mephenesin may be an NMDA receptor antagonist.[7] Mephenesin was previously used in France as an OTC muscle relaxant called Décontractyl but was taken out of production by Sanofi Aventis and due to a French Health Ministry decree in July 2019. Mephenesin is, however, still available in Italy.

See also

  • Bachmeyer C, Blum L, Fléchet M, Duriez P, Cabane J, Imbert J (1996). "[Severe contact dermatitis caused by mephenesin]". Ann Dermatol Venereol. 123 (3): 185–7. PMID 8761781.
  • Ono H, Nakamura T, Ito H, Oka J, Fukuda H (1987). "Rigidity in rats due to radio frequency decerebration and effects of chlorpromazine and mephenesin". Gen Pharmacol. 18 (1): 57–9. doi:10.1016/0306-3623(87)90170-4. PMID 3557053.

References

  1. ^ "Mephenesin Definition & Meaning". Merriam-Webster Medical.
  2. ^ Berger FM (December 1947). "The mode of action of myanesin". British Journal of Pharmacology and Chemotherapy. 2 (4): 241–50. doi:10.1111/j.1476-5381.1947.tb00341.x. PMC 1509790. PMID 19108125.
  3. ^ "Mephenesin". MIMS.
  4. ^ Ban TA (2006). "The role of serendipity in drug discovery". Dialogues in Clinical Neuroscience. 8 (3): 335–44. doi:10.31887/DCNS.2006.8.3/tban. PMC 3181823. PMID 17117615.
  5. ^ "Mephenesin". Drugs.com.
  6. ^ Huf, Ernst; et al. (1959). "Comparative Plasma Levels of Mephenesin, Mephenesin Carbamate and Methocarbamol". Proceedings of the Society for Experimental Biology and Medicine. 102 (2). Experimental Biology & Medicine: 276–7. doi:10.3181/00379727-102-25218. PMID 14403806. S2CID 37483102. Retrieved 8 January 2014.
  7. ^ Keshavarz M, Showraki A, Emamghoreishi M (2013). "Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice". Iran J Med Sci. 38 (2): 116–21. PMC 3700057. PMID 23825891.